Shares of Celgene Corporation (NASDAQ:CELG) have been given an average rating of “Buy” by the thirty ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $147.39.

CELG has been the subject of a number of recent analyst reports. Jefferies Group LLC set a $154.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Saturday, May 13th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Mizuho lifted their target price on shares of Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, June 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $138.00 target price on shares of Celgene Corporation in a research note on Wednesday, May 24th.

In other news, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 263,011 shares of company stock worth $35,078,473. Corporate insiders own 0.95% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Thompson Davis & CO. Inc. boosted its position in shares of Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares during the last quarter. Motco boosted its position in shares of Celgene Corporation by 306.9% during the 1st quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the 1st quarter valued at about $118,000. Balentine LLC boosted its position in shares of Celgene Corporation by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 481 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its position in shares of Celgene Corporation by 60.9% during the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 412 shares during the last quarter. 79.43% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/09/celgene-corporation-celg-receives-consensus-rating-of-buy-from-analysts.html.

Celgene Corporation (CELG) traded down 0.89% on Friday, hitting $140.50. 3,675,872 shares of the stock traded hands. The firm has a 50-day moving average price of $134.31 and a 200-day moving average price of $126.68. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $142.64. The company has a market capitalization of $109.92 billion, a PE ratio of 43.51 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period last year, the business earned $1.44 EPS. Analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.